Dong Sung Bio Pharm.Co.,Ltd. announced a private placement of round 32 Non-guaranteed Private Equity Bonds with Preemptive Rights for gross proceeds of KRW 8,500,000,000 on August 13, 2021. The transaction will include participation from Mirae Asset Securities Co., Ltd., BNK Securities Co., Ltd., Investment Arm, Orion New Deal Stepping Stone Professional Investment Private Equity Trust No. 1, a fund managed by Orion Capital Management, BFA Co.,Ltd., IBK Capital Corporation for KRW 1,000,000,000 each, Zebra Investment Management Co., Ltd. for KRW 3,000,000,000 and Darwin Venture Capital Co., Ltd., a fund managed by Dawin Technology Finance Co., Ltd. for KRW 500,000,000.

The bonds are zero coupon bonds with no yield to maturity, will mature on August 23, 2026 and are being issued at par value. The bonds are fully convertible into 824,682 common shares at a fixed conversion price of KRW 10,307 per share from August 23, 2022 to July 23, 2026. The transaction has been approved by the board of directors of the company.

The subscription date is on August 18, 2021 and the payment date is on August 23, 2021. The bonds are subject to a hold period of one year.